This “Pulmonary Sarcoidosis - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Pulmonary Sarcoidosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Sarcoidosis is a rare disease caused by inflammation. It usually occurs in the lungs and lymph nodes, but it can occur in almost any organ. Sarcoidosis in the lungs is called pulmonary sarcoidosis. It causes small lumps of inflammatory cells in the lungs. These lumps are called granulomas and can affect how the lungs work. The cause of pulmonary sarcoidosis is unknown. Experts think that bacteria, viruses, or chemicals might trigger the disease. It may also be genetic. The following are the most common symptoms of pulmonary sarcoidosis. Symptoms may include: Shortness of breath, which often gets worse with activity, dry cough that will not go away, chest pain, wheezing. Pulmonary sarcoidosis is diagnosed through Chest X-ray, CT scan, pulmonary function tests, blood tests, bronchoscopy, bronchoalveolar lavage, lung biopsy. Treatment is generally done to control symptoms and improve the function of organs affected by the disease. Steroid medicine, such as prednisone, may help reduce inflammation. Other medicines, such as methotrexate, may be used in severe cases or if steroids don't work.
The companies and academics are working to assess challenges and seek opportunities that could influence Pulmonary Sarcoidosis R&D. The therapies under development are focused on novel approaches for Pulmonary Sarcoidosis.
This segment of the Pulmonary Sarcoidosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
CMK 389: Novartis
CMK 389 acts as inhibitors of Interleukin 18. It is being developed by Novartis for Pulmonary sarcoidosis and is currently in phase II stage of development.
ATYR1923: aTyr Pharma
ATYR1923 is a potential first-in-class, disease modifying therapy for patients with severe inflammatory lung diseases with high unmet medical need. ATYR1923 works by selectively modulating Neuropilin-2 (NRP2) to downregulate the innate and adaptive immune responses in uncontrolled inflammatory disease states to resolve inflammation and prevent subsequent fibrosis. ATYR1923 is conducting a Phase 1b/2a clinical trial in pulmonary sarcoidosis, a major form of interstitial lung disease (ILD), a group of immune-mediated disorders that cause progressive fibrosis of the lung.
There are approx. 10+ key companies which are developing the Pulmonary Sarcoidosis. The companies which have their Pulmonary Sarcoidosis drug candidates in the most advanced stage, i.e. Phase III include, Corbus Pharmaceuticals.
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Pulmonary Sarcoidosis therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pulmonary Sarcoidosis drugs.
Geography Covered
- Global coverage
Pulmonary Sarcoidosis Understanding
Pulmonary Sarcoidosis: Overview
Sarcoidosis is a rare disease caused by inflammation. It usually occurs in the lungs and lymph nodes, but it can occur in almost any organ. Sarcoidosis in the lungs is called pulmonary sarcoidosis. It causes small lumps of inflammatory cells in the lungs. These lumps are called granulomas and can affect how the lungs work. The cause of pulmonary sarcoidosis is unknown. Experts think that bacteria, viruses, or chemicals might trigger the disease. It may also be genetic. The following are the most common symptoms of pulmonary sarcoidosis. Symptoms may include: Shortness of breath, which often gets worse with activity, dry cough that will not go away, chest pain, wheezing. Pulmonary sarcoidosis is diagnosed through Chest X-ray, CT scan, pulmonary function tests, blood tests, bronchoscopy, bronchoalveolar lavage, lung biopsy. Treatment is generally done to control symptoms and improve the function of organs affected by the disease. Steroid medicine, such as prednisone, may help reduce inflammation. Other medicines, such as methotrexate, may be used in severe cases or if steroids don't work.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Pulmonary Sarcoidosis R&D. The therapies under development are focused on novel approaches for Pulmonary Sarcoidosis.
Pulmonary Sarcoidosis Emerging Drugs Chapters
This segment of the Pulmonary Sarcoidosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Pulmonary Sarcoidosis Emerging Drugs
CMK 389: Novartis
CMK 389 acts as inhibitors of Interleukin 18. It is being developed by Novartis for Pulmonary sarcoidosis and is currently in phase II stage of development.
ATYR1923: aTyr Pharma
ATYR1923 is a potential first-in-class, disease modifying therapy for patients with severe inflammatory lung diseases with high unmet medical need. ATYR1923 works by selectively modulating Neuropilin-2 (NRP2) to downregulate the innate and adaptive immune responses in uncontrolled inflammatory disease states to resolve inflammation and prevent subsequent fibrosis. ATYR1923 is conducting a Phase 1b/2a clinical trial in pulmonary sarcoidosis, a major form of interstitial lung disease (ILD), a group of immune-mediated disorders that cause progressive fibrosis of the lung.
Pulmonary Sarcoidosis: Therapeutic Assessment
This segment of the report provides insights about the different Pulmonary Sarcoidosis drugs segregated based on following parameters that define the scope of the report, such as:
Major Players working on Pulmonary Sarcoidosis
There are approx. 10+ key companies which are developing the Pulmonary Sarcoidosis. The companies which have their Pulmonary Sarcoidosis drug candidates in the most advanced stage, i.e. Phase III include, Corbus Pharmaceuticals.
Phases
This report covers around 10+ products under different phases of clinical development like
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Pulmonary Sarcoidosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
Products have been categorized under various Molecule types such as
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Pulmonary Sarcoidosis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Pulmonary Sarcoidosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pulmonary Sarcoidosis drugs.
Pulmonary Sarcoidosis Report Insights
- Pulmonary Sarcoidosis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Pulmonary Sarcoidosis Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Scenario and Emerging Therapies:
- How many companies are developing Pulmonary Sarcoidosis drugs?
- How many Pulmonary Sarcoidosis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Pulmonary Sarcoidosis?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Pulmonary Sarcoidosis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Pulmonary Sarcoidosis and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Novartis
- aTyr Pharma
- Relief Therapeutics
- AI Therapeutics
- SarcoMed USA
Key Products
- CMK389
- ATYR1923
- RLF-100
- LAM-001
- SM001
Table of Contents
IntroductionExecutive Summary
Pulmonary Sarcoidosis: Overview
- Structure
- Mechanism of Action
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Pulmonary Sarcoidosis- Analytical Perspective
In-depth Commercial Assessment
- Pulmonary Sarcoidosis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Pulmonary Sarcoidosis Collaboration Deals
- Company-Company Collaborations (Licensing/Partnering) Analysis
- Company-University Collaborations (Licensing/Partnering) Analysis
Late Stage Products (Phase III)
- Comparative Analysis
Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
CMK389: Novartis
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products (Phase I/II)
- Comparative Analysis
ATYR1923: aTyr Pharma
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products (Phase I)
- Comparative Analysis
LAM-001: AI Therapeutics
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Pulmonary Sarcoidosis Key Companies
Pulmonary Sarcoidosis Key Products
Pulmonary Sarcoidosis- Unmet Needs
Pulmonary Sarcoidosis- Market Drivers and Barriers
Pulmonary Sarcoidosis- Future Perspectives and Conclusion
Pulmonary Sarcoidosis Analyst Views
Pulmonary Sarcoidosis Key Companies
AppendixList of Tables
Table 1 Total Products for Pulmonary Sarcoidosis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Pulmonary Sarcoidosis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned
A selection of companies mentioned in this report includes:
- Novartis
- aTyr Pharma
- Relief Therapeutics
- AI Therapeutics
- SarcoMed USA
